{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:28:21Z","timestamp":1791365301690,"version":"4.3.1"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Simpson Family Breast Cancer Research and Detection Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Presence of circulating tumor DNA (ctDNA) is prognostic in solid tumors treated with curative intent. Studies have evaluated ctDNA at specific \u201clandmark\u201d or multiple \u201csurveillance\u201d time points. However, variable results have led to uncertainty about its clinical validity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A PubMed search identified relevant studies evaluating ctDNA monitoring in solid tumors after curative intent therapy. Odds ratios for recurrence at both landmark and surveillance time points for each study were calculated and pooled in a meta-analysis using the Peto method. Pooled sensitivity and specificity weighted by individual study inverse variance were estimated and meta-regression using linear regression weighted by inverse variance was performed to explore associations between patient and tumor characteristics and the odds ratio for disease recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 39 studies identified, 30 (1924 patients) and 24 studies (1516 patients) reported on landmark and surveillance time points, respectively. The pooled odds ratio for recurrence at landmark was 15.47 (95% confidence interval = 11.84 to 20.22) and at surveillance was 31.0 (95% confidence interval = 23.9 to 40.2). The pooled sensitivity for ctDNA at landmark and surveillance analyses was 58.3% and 82.2%, respectively. The corresponding specificities were 92% and 94.1%, respectively. Prognostic accuracy was lower with tumor agnostic panels and higher with longer time to landmark analysis, number of surveillance draws, and smoking history. Adjuvant chemotherapy negatively affected landmark specificity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although prognostic accuracy of ctDNA is high, it has low sensitivity, borderline high specificity, and therefore modest discriminatory accuracy, especially for landmark analyses. Adequately designed clinical trials with appropriate testing strategies and assay parameters are required to demonstrate clinical utility.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jncics\/pkad040","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T14:43:51Z","timestamp":1685198631000},"source":"Crossref","is-referenced-by-count":12,"title":["Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-1573","authenticated-orcid":false,"given":"Abhenil","family":"Mittal","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolacion","family":"Molto Valiente","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Tamimi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9195-9894","authenticated-orcid":false,"given":"Massimo","family":"Di Iorio","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Al-Showbaki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Jordan University Hospital and School of Medicine, The University of Jordan , Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-0998","authenticated-orcid":false,"given":"David W","family":"Cescon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-525X","authenticated-orcid":false,"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"issue":"21","key":"2023070319533821000_pkad040-B1","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023070319533821000_pkad040-B2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2023070319533821000_pkad040-B3","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"9814","key":"2023070319533821000_pkad040-B4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"2023070319533821000_pkad040-B5","doi-asserted-by":"crossref","first-page":"100184","DOI":"10.1016\/j.esmoop.2021.100184","article-title":"How I treat stage II colon cancer patients","volume":"6","author":"Taieb","year":"2021","journal-title":"ESMO Open"},{"key":"2023070319533821000_pkad040-B6","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1200\/EDBK_239283","article-title":"Approaches to high-risk resected stage II and III melanoma","volume":"39","author":"Yushak","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2023070319533821000_pkad040-B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2023070319533821000_pkad040-B8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9938","key":"2023070319533821000_pkad040-B9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"2023070319533821000_pkad040-B10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2023070319533821000_pkad040-B11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/oncolo\/oyac101","article-title":"Ovarian function suppression: a deeper consideration of the role in early breast cancer and its potential impact on patient outcomes: a consensus statement from an international expert panel","volume":"27","author":"Arboleda","year":"2022","journal-title":"Oncologist"},{"issue":"suppl 16","key":"2023070319533821000_pkad040-B12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2022.40.16_suppl.579","article-title":"Three-year disease-free survival in randomized trials of chemotherapy and HER2-targeted therapy: a meta-analysis","volume":"40","author":"Mittal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023070319533821000_pkad040-B13","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdr470","article-title":"Follow-up with CA125 after primary therapy of advanced ovarian cancer: In favor of continuing to prescribe CA125 during follow-up","volume":"22","author":"Pignata","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"2023070319533821000_pkad040-B14","first-page":"CD011134","article-title":"Blood CEA levels for detecting recurrent colorectal cancer","volume":"2015","author":"Nicholson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"9747","key":"2023070319533821000_pkad040-B15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"2023070319533821000_pkad040-B16","first-page":"1","author":"Wolf"},{"issue":"12","key":"2023070319533821000_pkad040-B17","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"2023070319533821000_pkad040-B18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2011.04.014","article-title":"Minimal residual disease in solid neoplasia: new frontier or red-herring?","volume":"38","author":"Mordant","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"2023070319533821000_pkad040-B19","doi-asserted-by":"crossref","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","article-title":"Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2023070319533821000_pkad040-B20","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"2023070319533821000_pkad040-B21","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2023070319533821000_pkad040-B22","author":"Wells"},{"key":"2023070319533821000_pkad040-B23","author":"Deeks"},{"issue":"9","key":"2023070319533821000_pkad040-B24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"issue":"12","key":"2023070319533821000_pkad040-B25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","article-title":"Indexes and boundaries for \u201cquantitative significance\u201d in statistical decisions","volume":"43","author":"Burnand","year":"1990","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"2023070319533821000_pkad040-B26","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)\u2014a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"issue":"9","key":"2023070319533821000_pkad040-B27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2023070319533821000_pkad040-B28","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","article-title":"Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"2023070319533821000_pkad040-B29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"2023070319533821000_pkad040-B30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"issue":"5","key":"2023070319533821000_pkad040-B31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"key":"2023070319533821000_pkad040-B32","doi-asserted-by":"crossref","first-page":"561598","DOI":"10.3389\/fonc.2020.561598","article-title":"Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"2023070319533821000_pkad040-B33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3322\/caac.21650","article-title":"Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2023070319533821000_pkad040-B34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-020-01618-6","article-title":"Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Xu","year":"2020","journal-title":"BMC Med"},{"issue":"1","key":"2023070319533821000_pkad040-B35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12885-018-4076-4","article-title":"Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort","volume":"18","author":"Lafourcade","year":"2018","journal-title":"BMC Cancer"},{"issue":"22","key":"2023070319533821000_pkad040-B36","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1002\/cncr.24625","article-title":"Local recurrence after surgery for early stage lung cancer","volume":"115","author":"Kelsey","year":"2009","journal-title":"Cancer"},{"key":"2023070319533821000_pkad040-B37","author":"NRG Oncology","year":"2022"},{"key":"2023070319533821000_pkad040-B38","author":"Roche","year":"2022"},{"key":"2023070319533821000_pkad040-B39","author":"Institute of Cancer Research, United Kingdom","year":"2022"},{"key":"2023070319533821000_pkad040-B40","author":"AstraZeneca"},{"key":"2023070319533821000_pkad040-B41"},{"key":"2023070319533821000_pkad040-B42","author":"IFOM. The FIRC Institute of Molecular Oncology","year":"2022"},{"issue":"13","key":"2023070319533821000_pkad040-B43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"2023070319533821000_pkad040-B44","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"2023070319533821000_pkad040-B45","author":"Bardia","year":"2021"},{"key":"2023070319533821000_pkad040-B46","year":"2022"},{"issue":"18","key":"2023070319533821000_pkad040-B47","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"2023070319533821000_pkad040-B48","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1200\/JCO.2018.36.15_suppl.12003","article-title":"Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study","volume":"36","author":"Swanton","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"2023070319533821000_pkad040-B49","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-19-1213","article-title":"Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023070319533821000_pkad040-B50","doi-asserted-by":"crossref","first-page":"e2017421118","DOI":"10.1073\/pnas.2017421118","article-title":"Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy","volume":"118","author":"Jin","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2023070319533821000_pkad040-B51","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023070319533821000_pkad040-B52","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"2023070319533821000_pkad040-B53","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"2023070319533821000_pkad040-B54","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.7150\/thno.59644","article-title":"Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"7655","key":"2023070319533821000_pkad040-B55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"16","key":"2023070319533821000_pkad040-B56","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","article-title":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","volume":"25","author":"Groot","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023070319533821000_pkad040-B57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/1878-0261.13116","article-title":"Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer","volume":"16","author":"Waldeck","year":"2022","journal-title":"Mol Oncol"},{"issue":"403","key":"2023070319533821000_pkad040-B58","doi-asserted-by":"crossref","first-page":"eaan2415","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"504","key":"2023070319533821000_pkad040-B59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"2023070319533821000_pkad040-B60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","article-title":"Detection of solid tumor Molecular Residual Disease\u00a0(MRD) using circulating tumor DNA (ctDNA)","volume":"23","author":"Chin","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"24","key":"2023070319533821000_pkad040-B61","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2023070319533821000_pkad040-B62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12885-018-4138-7","article-title":"Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study","volume":"18","author":"Gao","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"2023070319533821000_pkad040-B63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/cancers11040550","article-title":"Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. A systematic review and meta-analysis","volume":"11","author":"Petrelli","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2023070319533821000_pkad040-B64","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"22","key":"2023070319533821000_pkad040-B65","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.3390\/cancers13225698","article-title":"Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors","volume":"13","author":"Larrib\u00e8re","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7794","key":"2023070319533821000_pkad040-B66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","article-title":"Tobacco exposure and somatic mutations in normal human bronchial epithelium","volume":"578","author":"Yoshida","year":"2020","journal-title":"Nature"},{"issue":"6","key":"2023070319533821000_pkad040-B67","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"issue":"suppl 16","key":"2023070319533821000_pkad040-B68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2022.40.16_suppl.103","article-title":"Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor\u2013positive, HER2-negative breast cancer (CHiRP)","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023070319533821000_pkad040-B69","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"2023070319533821000_pkad040-B70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"2023070319533821000_pkad040-B71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.004","article-title":"Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)","volume":"159","author":"Benhaim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023070319533821000_pkad040-B72","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12885-021-08508-x","article-title":"Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"issue":"8","key":"2023070319533821000_pkad040-B73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/1878-0261.12729","article-title":"The effect of surgical trauma on circulating free DNA levels in cancer patients\u2014implications for studies of circulating tumor DNA","volume":"14","author":"Henriksen","year":"2020","journal-title":"Mol Oncol"},{"issue":"1","key":"2023070319533821000_pkad040-B74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-19-1996","article-title":"MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer","volume":"26","author":"Khakoo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023070319533821000_pkad040-B75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/PO.20.00220","article-title":"Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer","volume":"5","author":"McDuff","year":"2021","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"20","key":"2023070319533821000_pkad040-B76","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2023070319533821000_pkad040-B77","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","article-title":"Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer","volume":"23","author":"Sch\u00f8ler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023070319533821000_pkad040-B78","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"2023070319533821000_pkad040-B79","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"issue":"3","key":"2023070319533821000_pkad040-B80","doi-asserted-by":"crossref","first-page":"e221093","DOI":"10.1001\/jamanetworkopen.2022.1093","article-title":"Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and carcinoembryonic antigen levels in patients with resected colorectal cancer","volume":"5","author":"Fakih","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"346","key":"2023070319533821000_pkad040-B81","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"8","key":"2023070319533821000_pkad040-B82","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaoncol.2019.0512","article-title":"Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2023070319533821000_pkad040-B83","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"2023070319533821000_pkad040-B84","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"issue":"14","key":"2023070319533821000_pkad040-B85","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"302","key":"2023070319533821000_pkad040-B86","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"2023070319533821000_pkad040-B87","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2023070319533821000_pkad040-B88","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"issue":"18","key":"2023070319533821000_pkad040-B89","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free dna in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkad040\/50463821\/pkad040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/4\/pkad040\/50790147\/pkad040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/4\/pkad040\/50790147\/pkad040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:51:20Z","timestamp":1702533080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkad040\/7181286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkad040","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,5,27]]},"article-number":"pkad040"}}